article thumbnail

The Most Engaging Decision You’ll Read All Year – Five Stars

FDA Law Blog

FDA , Petitioners, a liquid nicotine manufacturer, sued FDA arguing that the Agency was arbitrary and capricious in rejecting the Petitioner’s Premarket Tobacco Application (“PMTA”) in violation of the Administrative Procedure Act (“APA”). FDA also directed manufacturers to produce detailed marketing plans.

article thumbnail

Common Skincare Ingredients that Are Linked to Cancer

Health One Family Medicine

As with parabens, manufacturers add them to reduce the risk of bacterial contamination. Contaminated Talc In 2019, the FDA advised consumers to avoid using certain cosmetic products because they tested positive for asbestos. The post Common Skincare Ingredients that Are Linked to Cancer appeared first on Health One Family Medicine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

An Arm and a Leg: The Prescription Drug Playbook, Part I

Physician's Weekly

Dozens of listeners responded with their stories, including Bob, who is being identified only by his first name to guard his family’s privacy and whose daughter has epilepsy. Bob’s journey here begins in 2019 — the first day of high school for his daughter, Mary. Dan: Another addition: Manufacturer coupons.

article thumbnail

This Thanksgiving, Be Thankful for Family and Food(borne Illness Prevention)

FDA Law Blog

Reported illnesses began just three days before Thanksgiving in 2017, but due to the unknown source of the turkey at the center of the outbreak, the Centers for Disease Control and Prevention (CDC) did not conclude the outbreak investigation until April 2019. Two days before Thanksgiving the following year, the CDC warned U.S.

article thumbnail

Direct-to-consumer advertising distorts prescription drugs’ benefits and costs

Common Sense Family Doctor

In 1998, a Letter to the Editor in American Family Physician expressed concerns about the relatively new practice of pharmaceutical advertising directly to patients. The annual price of risankizumab is $288,000, so this is still a huge bargain for the company given the potential returns. Kennedy, Jr.’s

article thumbnail

Gabapentinoids – Gabapentin and Pregabalin: Tasce Bongiovanni, Donovan Maust and Nisha Iyer

GeriPal

AFP 2019 Gabapentin for chronic neuropathic pain in adults. And for that reason, there was actually an enormous lawsuit, and the manufacturer was fined, now I think 20 years ago, in the millions and millions of dollars for off-label prescribing. These are families who are in distress. These are patients who are in distress.